Amerikanische Gesellschaft für Hirudotherapie

Anticoagulant peptide LR from Whitmania pigra ameliorates cerebral ischemia-reperfusion injury

Preclinical study published in Brain Research (2026)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikSpeichel-PharmakologieArzneimittelentwicklungLiu R et al. · Brain research, 2026

Abstract

BACKGROUND: Ischemic stroke (IS) is a leading cause of death and disability worldwide. Hypercoagulability and thrombus formation play critical roles in its pathogenesis. Leech-derived peptides, especially those obtained from Whitmania pigra, have demonstrated potential antithrombotic and neuroprotective effects. This study aimed to investigate the therapeutic efficacy and underlying mechanisms of a leech peptide in a rat model of cerebral ischemia/reperfusion injury. METHODS: Adult male Sprague-Dawley rats were subjected to middle cerebral artery occlusion followed by reperfusion to establish the IS model. Rats received low-dose or high-dose leech peptide, edaravone as a positive control, or saline. Behavioral assessments, infarct volume measurement, laser speckle imaging for cerebral perfusion, and histopathology were performed. Hemorheology and coagulation parameters were analyzed. Additionally, thrombin levels and fibrinolytic factors were evaluated using ELISA. Biosafety was assessed through hemolysis and histological evaluation of major organs. RESULTS: Leech peptide significantly reduced infarct volume, improved neurological scores, enhanced cerebral perfusion, and preserved brain tissue structure. It modulated thrombin-related parameters, ameliorated coagulation dysfunction, and modulated fibrinolysis-associated factors, thereby contributing to the restoration of coagulation-fibrinolysis homeostasis. Low-dose treatment showed comparable or superior efficacy to the high dose with better safety. No significant toxicity or hemolysis was observed. CONCLUSIONS: Leech peptide derived from Whitmania pigra exerts neuroprotective effects in cerebral ischemia/reperfusion injury through anticoagulation and thrombolysis. These findings support its potential as a novel candidate for IS therapy. TRIAL REGISTRATION: Not applicable. This study did not involve human participants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsRats, Sprague-DawleyMaleReperfusion InjuryRatsLeechesNeuroprotective AgentsAnticoagulantsPeptidesBrain IschemiaDisease Models, AnimalInfarction, Middle Cerebral Artery

Zusammenfassung

Anticoagulant peptide LR from Whitmania pigra reduces infarct volume and improves neurological scores in murine cerebral ischemia-reperfusion model via thrombin inhibition.

Warum dies für die Hirudotherapie relevant ist

This study investigated the therapeutic efficacy of a leech-derived peptide from Whitmania pigra in a rat model of cerebral ischemia/reperfusion injury (middle cerebral artery occlusion), assessing neurological scores, infarct volume, cerebral perfusion via laser speckle imaging, hemorheology, coagulation parameters, thrombin levels, and fibrinolytic factors. The leech peptide significantly reduced infarct volume, improved neurological scores and cerebral perfusion, modulated thrombin-related parameters and fibrinolysis, and restored coagulation-fibrinolysis homeostasis, with the low dose showing comparable or superior efficacy and no significant toxicity or hemolysis. These findings are relevant to hirudotherapy as they demonstrate neuroprotective and antithrombotic effects of a specific leech peptide in a stroke model. However, this study was conducted exclusively in rats; no human data are presented, and clinical translation would require further validation.

Zitation

Anticoagulant peptide LR from Whitmania pigra ameliorates cerebral ischemia-reperfusion injury.

Liu R et al. · Brain research, 2026

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.